Humacyte Inc. (HUMA)
| Bid | 1.66 |
| Market Cap | 216.16M |
| Revenue (ttm) | 7.23M |
| Net Income (ttm) | 0 |
| EPS (ttm) | -1.26 |
| PE Ratio (ttm) | -1.33 |
| Forward PE | -9.22 |
| Analyst | Buy |
| Ask | 2.02 |
| Volume | 3,079,696 |
| Avg. Volume (20D) | 3,454,577 |
| Open | 1.55 |
| Previous Close | 1.55 |
| Day's Range | 1.55 - 1.70 |
| 52-Week Range | 1.15 - 9.97 |
| Beta | 1.62 |
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without i...
Analyst Forecast
According to 7 analyst ratings, the average rating for HUMA stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 733.33% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
Humacyte, Inc. (HUMA) Q4 2024 Earnings Conference Call TranscriptHumacyte, Inc. (NASDAQ:HUMA ) Q4 2024 Earnings Conference Call March 27, 2025 8:30 AM ET Company Participants Thomas Johnson - Director, Corporate Communications, LifeSci Advisors, IR Laura Niklason -...
